Retinoids and vitamin C increase collagen production. GHK-Cu does something different: it tells tissue how to organize the collagen it already makes. Aging skin doesn't just have less collagen — it has worse-organized collagen, disrupted microcirculation, and a cellular environment biased toward defense rather than repair. GHK-Cu is endogenous; plasma levels fall ~60% between ages 20 and 60, tracking the slowdown in wound healing and skin thinning. Microarray studies show it shifting expression across 4,000+ genes, moving cells from damage-response toward organized repair. Injectable GHK-Cu sits at the core of the GLOW protocol alongside BPC-157 and TB-500.

How GHK-Cu Works

GHK-Cu carries copper to sites where skin and connective tissue are repairing. Copper is a cofactor for enzymes that cross-link collagen and elastin and manage matrix turnover. In the right range, it shifts tissue signaling from "defense" into regeneration.

Collagen and elastin

Increases types I and III collagen and elastin, activates lysyl oxidase to cross-link fibers, and keeps matrix metalloproteinases in balance so damaged collagen clears while new collagen deposits in organized patterns — better-aligned, better-cross-linked collagen that feels firm rather than thick and ropey.

Scar remodeling

Modulates chaotic scar collagen so raised or discolored scars flatten, soften, and blend over months (not days).

Blood flow and repair tone

Supports new capillary formation and local perfusion — better nutrient delivery and a smoother transition from early repair to maintenance; skin looks less dull, especially in areas that stayed red after procedures.

Gene expression

Modulates 4,000+ human genes — turning up tissue remodeling and wound-healing programs while turning down inflammation and fibrosis. A computational study (Broad Institute Connectivity Map) found GHK matched a signature reversing COPD lung-tissue breakdown, suggesting a broad tissue-repair signal — a single computational finding needing direct confirmation.

Timeline

• Weeks 2–4: smoother texture, improved hydration, less reactivity

• Weeks 4–8: fine lines soften, crepey areas improve, early scar changes

• Weeks 8–12+: firmer feel, better "snap," mature scar changes (flatter, paler, softer)

Benefits

• Better structure: firmer feel and more "snap" in lax/crepey areas

• Smoother texture: gradual softening of fine lines and roughness

• Scar improvement: raised/discolored scars flatten and blend

• Calmer skin: lower reactivity, less prolonged redness after procedures

• Durable results: microneedling "holds" better when matrix remodels cleanly

Injectable vs Topical

Protocols

Injectable: 1–2.5 mg SubQ, 2–3×/week for 6–8 weeks; regional or grid pattern around scars or lax zones; mind placement depth, procedure timing, and substrate. Work with a clinician who understands peptide pharmacology and dermal anatomy. See the reconstitution calculator.

Topical (alternative): 0.1–0.3% for ongoing facial use, 0.5–2% for scars; nightly to face/neck for texture, twice-daily to scars for 8–12 weeks; separate from strong acids/high-strength retinoids; layer after hydrating steps, before occlusives.

Substrate: adequate protein, sufficient vitamin C (collagen hydroxylation), stable sleep, lower background inflammation.

GHK-Cu for Hair

The same mechanisms (blood flow, reduced inflammation, collagen support) apply to follicles: promotes scalp angiogenesis, supports the dermal papilla, and may counteract DHT (less established). Typical results: reduced shedding over 2–3 months, improved scalp condition, thicker-feeling hair, better when combined with minoxidil or microneedling. Topical 0.5–2% scalp serums daily (often after dermarolling); injectable mesotherapy is more experimental; allow 3–6 months. Not a standalone hair-loss treatment.

Side Effects and Safety

Works in a narrow signaling window — more is not better. Avoid on open wounds until basic closure; space from strong acids/aggressive actives; mind overall copper load. Contraindications: Wilson's disease or copper-handling disorders; active malignancy in the treatment area; pregnancy/breastfeeding; allergy to formulation components.